Saturday 17 October 2026
Export ICU’s income statement to Excel — free account
SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, up 814.1% from fiscal 2024. In the quarter to June 2026, revenue grew 82.0%, EPS grew 49.4% and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.93
0.13
−4.25%
Follow ICU
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 2,417.50 | 975.00 | 40.50 | 16.95 | 2.20 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 2,533.50 | 5,500.00 | 1,585.00 | 429.25 | 30.70 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 2 | 2 | 9 | 12 | 19 | 17 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.07 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 0 | 1 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | 100.00 | 95.71 | |||||
| EBT | — | — | — | — | 0 | (5) | (12) | (26) | (25) | (12) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (18,390.37) | (984.36) | |||||
| Net income | — | 0 | — | — | 0 | (5) | (12) | (26) | (25) | (12) | |||||
| Depreciation | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.36 | 0.60 | ||||
| Earnings | — | — | — | — | (0.61) | (158.72) | (371.15) | (302.50) | (66.30) | (5.86) | |||||
| Cash flow | — | — | — | — | (13.14) | (176.34) | (237.62) | (118.63) | (42.80) | (6.56) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | (13.14) | (176.34) | (237.62) | (118.63) | (42.80) | (6.56) | |||||
| Book value | — | — | — | — | 2.30 | (97.10) | (632.99) | (159.98) | (5.84) | 5.02 | |||||
| Shares, m | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 2 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 4.03 | |||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 0.48 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | (3.60) | |||||
| EV/FCF | — | — | — | — | — | — | — | — | (0.50) | 0.33 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (5) | (8) | (10) | (16) | (14) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | 0 | (5) | (8) | (10) | (16) | (14) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | (3) | (15) | (11) | (3) | 10 | ||||
| Total debt | — | — | — | — | 0 | 0 | 8 | 4 | — | — | |||||
| Net debt | — | — | — | — | 0 | 0 | 8 | 4 | (2) | (12) | |||||
| Shareholders’ equity | — | — | — | — | 0 | (3) | (21) | (14) | (2) | 10 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (1.93) | (1,053.89) | (669.60) | (800.85) | (607.76) | (129.15) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | (26.26) | 328.73 | 103.40 | 151.49 | 309.35 | (295.15) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
SeaStar Medical Holding Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CNSY Cerenome, Inc. | $14.3M | — (loss-making) | — (loss-making) | −70.43% (below 0%: shrinking) | n/m | −31.46% (below 0%: shrinking) | 100.00% | (2,203.65%) | Compare |
| CLVSQ Clovis Oncology, Inc. | $14.2M | — (loss-making) | — (loss-making) | −19.13% (below 0%: shrinking) | n/m | +11.83% (above 0%: growing) | 71.93% | (144.26%) | Compare |
| BCDA BioCardia, Inc. | $14.2M | — (loss-making) | — (loss-making) | −93.02% (below 0%: shrinking) | n/m | −5.15% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| RVLP RVL Pharmaceuticals PLC | $14.1M | — (loss-making) | — (loss-making) | −2.25% (below 0%: shrinking) | n/m | −734.24% (below 0%: shrinking) | 76.43% | (266.66%) | Compare |
| LPCN Lipocine Inc. | $13.9M | — (loss-making) | — (loss-making) | −69.48% (below 0%: shrinking) | n/m | −60.56% (below 0%: shrinking) | 100.00% | (1,495.11%) | Compare |
| KTTA Pasithea Therapeutics Corp. | $13.7M | — (loss-making) | — (loss-making) | +1,494.04% (above 0%: growing) | n/m | −21.68% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ICU SeaStar Medical Holding Corporation | $13.5M | — (loss-making) | — (loss-making) | +81.95% (above 0%: growing) | n/m | +0.43% (above 0%: growing) | 91.22% | (616.42%) | |
| HIND Vyome Holdings, Inc. | $13.4M | 0.0× | — (loss-making) | −46.00% (below 0%: shrinking) | n/m | −195.04% (below 0%: shrinking) | 43.33% | (3,194.81%) | Compare |
| ALLR Allarity Therapeutics, Inc. | $13.2M | — (loss-making) | — (loss-making) | — | n/m | +53.22% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $14.0M | — | — | −46.00% | — | −26.57% | 88.22% | (205.46%) |
SeaStar Medical Holding Corporation (ICU) key facts
- Strength: SeaStar Medical Holding Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, up 814.1% from fiscal 2024.
- SeaStar Medical Holding Corporation (ICU) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ICU traded at $2.93, a market capitalization of $13.5 million.
- Return on equity was −295.2% and debt-to-equity 0.00.
- Its Altman Z-score is −16.12 (distress zone) for fiscal 2025.